- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Biomed Res Int. 2018 Dec 23;2018:1269063. doi: 10.1155/2018/1269063. eCollection 2018.
The Removal of HBV in Plasma by Extracorporeal Immunoadsorption from Plasma: A Potential Therapy of Hepatitis B Patients.
Han Z1, Lu X1, Tang Y1, Yang Y1, Liu Q1, Cheng P2, Zhou L3, Wang Y1.
Author information
1
State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, China.
2
Department of Laboratory, Wuhan University Hospital, Wuhan 430072, China.
3
Animal Biosafety Level III Laboratory at the Center for Animal Experiment, Wuhan University School of Medicine, Wuhan 430071, China.
Abstract
Objective:
To establish a novel HBV specific immunoadsorbent for the removing of HBV particles.
Methods:
The anti-HBsAg monoclonal antibody was immobilized on sepharose beads to produce a sepharose anti-HBs column. Then the immunoadsorbent was evaluated and characterized by scanning electron microscopy. In addition, time-dependent effects of the eradication capacity of anti-HBsAg functionalized sepharose beads against HBV were investigated.
Results:
Proposed immunoadsorbents exhibited a favorable biocompatibility as well as specificity. With the optimized recycle time, the decontamination performance of HBV particles and quantity of HBsAg were assessed either by real-time quantitative PCR or ELISA, which showed that the immunoadsorbent could remove approximately 90% of the HBV and 90% of the HBsAg from human plasma samples.
Conclusions:
All these results indicated that the novel immunoadsorbent could effectively remove HBV particles and likely serve as a novel therapy option or at least supplementary for the treatment regimen of HBV.
PMID:
30671444
PMCID:
PMC6323487
DOI:
10.1155/2018/1269063 |
|